TBI Neurorehabilitation Grants for Veterans

Full Title:
BEACON Act of 2026

Summary#

This bill creates two time-limited VA grant programs to fund research and clinical trials of neurorehabilitation treatments for chronic mild traumatic brain injury (mTBI) in veterans. It directs the VA to give grants to nonprofits, academic institutions, and non-VA health providers to develop, test, train, and evaluate novel or integrative (including non-drug) treatments and to set up independent third‑party studies and trials. The stated policy goal is to improve mental health and long‑term recovery for veterans with mTBI, and to identify evidence-based practices and possible standards of care.

Key changes:

  • New TBI Innovation Grant Program (3-year pilot): VA must award grants for prospective randomized controlled trials and related activities focused on chronic mTBI in veterans.
  • Grant caps and priorities: No single grant under the Innovation program may exceed $5,000,000 per fiscal year; priority goes to applicants with TBI experience.
  • Independent research program: A separate research grant program will fund exploratory and larger collaborative projects and require the VA to engage an independent third‑party organization to administer studies and run randomized controlled trials.
  • Funding authorized: $30 million total for the Innovation Grant Program (FY2026–FY2028) and $10 million per year for the independent research program (FY2026–FY2028), for a combined authorization of $60 million across the 3 years.
  • Reporting and oversight: Annual reports, annual program evaluations, and a comprehensive report from the third‑party organization to Congress are required. Both programs end three years after enactment unless extended.

What it means for you#

  • Veterans with chronic mild TBI

    • May gain access to new clinical trials and non‑drug rehabilitation approaches tested under these grants.
    • Could benefit from training and outreach efforts aimed at improving awareness and access to innovative treatments.
    • The bill explicitly aims to measure effects on mental health and suicide risk among veterans with mTBI.

  • Researchers, academic institutions, and nonprofits

    • Can apply for grants to run pilot studies or larger collaborative projects on mTBI treatments.
    • Eligible organizations include nonprofits, academic institutions, and experienced non-VA health providers.
    • Grant sizes are specified: exploratory/pilot grants up to $625,000 and larger collaborative grants up to $1.5 million under the independent program; up to $5 million per year under the Innovation program.

  • Clinicians and non-VA providers

    • May receive training funded by grants to deliver new neurorehabilitation approaches.
    • Non-VA health care providers with neurorehabilitation expertise are eligible to receive grants.

  • Department of Veterans Affairs

    • Must create rules within 180 days, oversee grants, coordinate with the VA suicide prevention grant program, and perform annual evaluations.
    • May use existing VA mental health program funds or operating budget of the National Center for PTSD to run these programs.

  • Taxpayers

    • The bill authorizes federal funding for the programs (see Expenses). How much is newly appropriated versus reallocated from existing VA budgets is not specified.

  • What is unclear

    • The bill does not define how many Innovation Program grants will be awarded in total.
    • The process and criteria for selecting the independent third‑party organization are not detailed.
    • The bill does not provide a clinical definition of “chronic mild TBI” or precise eligibility rules for veteran participants.

Expenses#

Estimated public cost: The bill authorizes a total of $60,000,000 over fiscal years 2026–2028 ($30,000,000 for the TBI Innovation Grant Program and $10,000,000 per year for the independent research program, totaling $30,000,000), but it also allows the VA to use existing mental health and National Center for PTSD funds.

  • Direct authorizations: $30,000,000 authorized for the Innovation Grant Program for FY2026–2028; $10,000,000 authorized per year (total $30,000,000) for the independent research program for FY2026–2028.
  • Grant limits: Individual grants capped at $5,000,000 per fiscal year for the Innovation program; exploratory grants up to $625,000 and collaborative grants up to $1,500,000 under the independent program.
  • Administrative costs: The VA must develop regulations, oversee the program, perform annual evaluations, and engage an independent third‑party organization — these activities will carry administrative costs, but the bill does not provide a separate estimate.
  • Use of existing funds: The VA may use amounts already available for general mental health care or the operating budget of the National Center for PTSD, which could mean funds are reallocated from other VA activities.

Proponents' View#

A possible argument for the bill, based on its text:

  • The bill appears intended to speed development and testing of new neurorehabilitation treatments for veterans with chronic mTBI, especially non‑pharmacological and patient‑centered approaches.
  • It could be seen as improving evidence on which treatments work by requiring prospective randomized controlled trials and independent evaluation.
  • The bill appears designed to address mental health and suicide risk linked to mTBI by coordinating research with the VA’s suicide prevention grant program.
  • It could expand clinician training and community partnerships to increase access to promising treatments outside standard VA pathways.
  • The requirement for reports and annual evaluations could help identify best practices and inform VA policy and standards of care.

Opponents' View#

Reasonable concerns or limitations, based on the bill text:

  • One concern is that the bill allows use of existing VA mental health and PTSD center funds, which could reduce money available for other VA services unless new appropriations are provided.
  • The three‑year authorization is short; it may not be enough time to complete multi‑year randomized trials or to scale proven treatments into standard care.
  • The bill does not specify how many Innovation Program grants will be awarded, which makes it unclear how widely the $30 million will be distributed.
  • Selection and oversight details for the independent third‑party organization and grant recipients are vague, leaving questions about transparency and conflict‑of‑interest safeguards.
  • Administrative and evaluation requirements will add workload for the VA and the third‑party organization; the bill does not estimate those costs or staffing needs.